Leerink Partnrs Has Bearish Outlook for Danaher Q4 Earnings

Danaher Co. (NYSE:DHR) – Investment analysts at Leerink Partnrs dropped their Q4 2024 earnings per share estimates for shares of Danaher in a report issued on Tuesday, October 22nd. Leerink Partnrs analyst P. Souda now forecasts that the conglomerate will post earnings per share of $2.15 for the quarter, down from their previous estimate of $2.39. The consensus estimate for Danaher’s current full-year earnings is $7.59 per share.

Other analysts have also issued research reports about the company. Bank of America increased their price objective on Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a report on Wednesday, July 24th. Barclays decreased their price objective on Danaher from $285.00 to $275.00 and set an “equal weight” rating for the company in a report on Wednesday. Evercore ISI raised their target price on Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Raymond James lowered their price target on Danaher from $310.00 to $300.00 and set an “outperform” rating for the company in a research report on Wednesday. Finally, The Goldman Sachs Group increased their price objective on Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a report on Wednesday, July 24th. Seven investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $287.28.

Danaher Stock Performance

Shares of DHR opened at $256.00 on Thursday. Danaher has a 12 month low of $182.09 and a 12 month high of $281.70. The stock has a fifty day moving average price of $270.43 and a 200-day moving average price of $260.43. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33. The firm has a market cap of $189.62 billion, a PE ratio of 43.39, a P/E/G ratio of 4.49 and a beta of 0.83.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, beating the consensus estimate of $1.57 by $0.14. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The firm had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same quarter in the prior year, the business posted $2.02 EPS. The business’s revenue for the quarter was up 3.1% compared to the same quarter last year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be given a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.42%. The ex-dividend date of this dividend is Friday, September 27th. Danaher’s dividend payout ratio is currently 18.31%.

Insider Activity at Danaher

In related news, CEO Rainer Blair sold 9,007 shares of Danaher stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the completion of the transaction, the chief executive officer now directly owns 97,983 shares in the company, valued at approximately $27,435,240. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CFO Matthew Mcgrew sold 16,172 shares of the business’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $279.84, for a total value of $4,525,572.48. Following the completion of the sale, the chief financial officer now directly owns 29,407 shares in the company, valued at $8,229,254.88. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Rainer Blair sold 9,007 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the sale, the chief executive officer now owns 97,983 shares of the company’s stock, valued at $27,435,240. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 30,059 shares of company stock worth $8,400,897. 11.10% of the stock is owned by corporate insiders.

Institutional Trading of Danaher

A number of institutional investors and hedge funds have recently made changes to their positions in DHR. Tsfg LLC increased its position in shares of Danaher by 733.3% in the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after buying an additional 88 shares in the last quarter. CarsonAllaria Wealth Management Ltd. purchased a new stake in shares of Danaher in the second quarter valued at approximately $25,000. nVerses Capital LLC acquired a new stake in shares of Danaher in the second quarter worth approximately $25,000. Redmont Wealth Advisors LLC acquired a new stake in shares of Danaher in the first quarter worth approximately $30,000. Finally, MFA Wealth Advisors LLC acquired a new stake in shares of Danaher in the second quarter worth approximately $51,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.